Superstring Capital Management initiated a new position in Sionna Therapeutics (NASDAQ:SION), acquiring 180,593 shares in the fourth quarter. What happened According to a February 17, 2026, SEC filing, Superstring Capital Management reported a new stake in Sionna Therapeutics totaling 180,593 shares. The quarter-end value of the position stood at $7.43 million. What else to know This new position represents 3.98% of Superstring’s 13F reportable AUM as of December 31, 2025. Top holdings after the fil ...

Company Overview - Sionna Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for cystic fibrosis, targeting the underlying cause of the disease by addressing CFTR protein dysfunction [5][8] - The company operates a research-driven business model, generating value through the discovery and clinical development of novel therapies, with revenue potential primarily from future product approvals and licensing [8] Financial Performance - As of the latest report, Sionna Therapeutics has a market capitalization of $1.68 billion and a net income of -$75.27 million (TTM) [4] - The stock price was $37.32, reflecting a 118% increase over the past year, significantly outperforming the S&P 500's approximately 20% gain during the same period [7] Recent Developments - OrbiMed Advisors sold 143,304 shares of Sionna Therapeutics, valued at an estimated $5.43 million, during the fourth quarter, reducing its position to 2.99% of its 13F reportable AUM [2][7] - The quarter-end position value increased by $37.56 million, indicating both trading activity and price appreciation [2] Clinical Pipeline - Sionna Therapeutics is advancing its clinical pipeline, with a Phase 2a proof-of-concept trial for its NBD1 stabilizer SION-719 currently underway [10][11] - An early-stage trial studying combination therapies is expected to produce topline data in mid-2026 [11] Financial Flexibility - The company ended 2025 with approximately $310 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028 [10]

Summary of Sionna Therapeutics Conference Call Company Overview - **Company**: Sionna Therapeutics (NasdaqGM:SION) - **Focus**: Development of treatments for cystic fibrosis (CF) using differentiated NBD1 stabilizers - **History**: Formed in late 2019 as a spin-out from Sanofi, with a legacy of over 15 years of research dating back to Genzyme [2][3] Core Points and Arguments - **Unmet Need in CF**: Despite advancements, only one-third of CF patients achieve normal CFTR function, indicating a significant unmet need in the market [3][4] - **Market Opportunity**: The CF treatment market is currently valued at $12 billion and is projected to grow to $15 billion by the end of the decade [4][22] - **Unique Positioning**: Sionna is the only company focused on NBD1 stabilizers, which are considered unique and differentiated from existing modulators [5][4] - **Pipeline Development**: - **SION-719**: Lead program being tested as an add-on to the standard of care, Trikafta, in the PreciSION CF study [9][10] - **SION-451**: Anchoring the dual combination strategy, currently in a healthy volunteer study [9][10] - **Clinical Strategy**: The goal is to stabilize NBD1 and combine it with other correctors to achieve full CFTR function [8][17] Key Data and Milestones - **Phase 1 Data**: Both SION-719 and SION-451 showed promising results in achieving exposure targets necessary for clinical efficacy [12][15] - **Upcoming Data**: Results from the PreciSION CF study and the healthy volunteer study are expected by mid-2026 [10][18] - **Financial Position**: The company ended 2025 with $310 million in cash, providing a runway into 2028 [10][57] Additional Important Insights - **Safety Profile**: Initial phase 1 studies indicated a favorable safety and tolerability profile for both SION-719 and SION-451 [29][30] - **Drug-Drug Interactions (DDIs)**: The company is aware of potential DDIs and has selected complementary modulators with differentiated metabolic profiles [35][36] - **Trial Design**: The PreciSION CF study is designed as a two-way crossover, allowing patients to serve as their own controls, which enhances efficiency [20][21] - **Commercial Viability**: Both the add-on and dual combination strategies are seen as commercially attractive, with decisions on advancing based on data and capital availability [60] Conclusion - **Strategic Position**: Sionna is well-positioned to disrupt the CF treatment landscape with its NBD1 stabilizers and combination strategies, backed by strong clinical data and financial resources [23][24]

Summary of Sionna Therapeutics FY Conference Call Company Overview - **Company**: Sionna Therapeutics (NasdaqGM:SION) - **Focus**: Development of NBD1 mechanistic medicines for Cystic Fibrosis (CF) [1][2] Industry Context - **Cystic Fibrosis (CF)**: Despite advancements in CF treatments, a significant unmet need remains, with two-thirds of patients not achieving normal CFTR function [2][7] - **Current Treatments**: Existing therapies like Trikafta and Alyftrek partially correct CFTR function but do not stabilize NBD1, leaving room for improvement [10][11] Core Points and Arguments - **NBD1 Stabilizers**: Sionna aims to revolutionize CF treatment by focusing on NBD1 stabilizers, which could unlock additional CFTR function improvements [2][8] - **F508del Mutation**: The most common mutation causing CF, F508del, leads to instability in the NBD1 region, impairing protein functionality [8][10] - **Preclinical Data**: Sionna's preclinical data suggests that stabilizing NBD1 can significantly improve the protein's ability to function and traffic to the cell surface, showing nearly equivalent efficacy to the triple combination therapy of Trikafta [11][12] - **Dual Combination Therapy**: The company prioritizes developing a dual combination therapy that includes NBD1 as a foundational component, aiming for full normalization of CFTR function [12][146] Clinical Trials and Data - **Phase 2 PreciSION CF Study**: This study will evaluate SION-719 as an add-on to Trikafta, focusing on sweat chloride levels as a primary endpoint [32][33] - **Success Threshold**: The study is powered to detect a change of at least 10 millimoles per liter in sweat chloride, which historically correlates with clinically meaningful improvements in lung function (FEV1) [40][66] - **Sample Size**: The study will involve 16 patients in a two-way crossover design to minimize variability [74][75] Safety and Efficacy Considerations - **Safety Monitoring**: The company emphasizes a strong focus on safety parameters, including liver function tests, while balancing efficacy [172][176] - **Patient Tolerance**: A significant percentage of CF patients (20%) are intolerant to current modulators due to liver enzyme elevations, highlighting the need for new options [170][182] Competitive Landscape - **Vertex Pharmaceuticals**: Vertex previously attempted to target NBD1 but faced challenges due to the shallow binding pockets, leading to the perception of NBD1 as "undruggable" [28][30] - **AbbVie Case Study**: AbbVie's failure to develop a competitive triple combination therapy after Trikafta's launch is attributed to compound failure rather than assay failure [125][126] Future Directions - **Commercial Opportunities**: Sionna sees potential for both dual combination therapies and add-on treatments to existing therapies, aiming to provide more options for patients [146][147] - **Regulatory Engagement**: The company has had straightforward interactions with regulators and collaborates with the Cystic Fibrosis Foundation for trial design and guidance [195][196] Conclusion Sionna Therapeutics is positioned to address significant unmet needs in CF treatment through innovative NBD1 stabilizers, with ongoing clinical trials and a focus on both safety and efficacy. The company aims to provide new therapeutic options that could enhance patient outcomes in a competitive landscape dominated by existing therapies.

Drug Development and Pipeline - The company is developing novel medicines targeting the cystic fibrosis transmembrane conductance regulator (CFTR) protein, aiming to restore normal CFTR function for approximately 90% of cystic fibrosis patients who carry the F508del mutation[29]. - SION-719, a potent NBD1 stabilizer, is currently in a Phase 2a trial, with topline data expected in mid-2026, following positive Phase 1 results announced in June 2025[37][38]. - The company’s pipeline includes SION-451, also a potent NBD1 stabilizer, which is being evaluated in dual combinations with other modulators, with topline data anticipated in mid-2026[37][38]. - The ongoing Phase 2a PreciSION CF trial is evaluating SION-719 in combination with Trikafta, with topline data expected in mid-2026[83]. - The company has advanced both SION-451 and SION-719 to the next phase of development, targeting NBD1 stabilization for CF treatment[80]. - The company expects topline data from the Phase 1 dual combination trial of SION-451 in mid-2026[94]. - SION-109 is currently being evaluated in combination with SION-451 in a Phase 1 dual combination trial, following successful Phase 1 trials for safety and tolerability[137]. Treatment Efficacy and Patient Outcomes - The current standard of care, Trikafta, does not stabilize NBD1, and at least two-thirds of patients on Trikafta do not achieve normal CFTR function, defined as sweat chloride levels below 30 mmol/L[55]. - Approximately 69% of patients treated with Alyftrek did not achieve normal CFTR function, indicating a significant unmet need for more effective treatment options[56]. - Two-thirds of CF patients on Trikafta still have sweat chloride levels above normal, indicating ongoing CFTR dysfunction[58]. - A two-year interim study showed that while pulmonary exacerbations improved, they were not normalized, and mental health issues increased among patients on Trikafta[59]. - Alyftrek demonstrated non-inferiority to Trikafta, with sweat chloride improvements of approximately 3 to 8 mmol/L, but 69% of patients did not achieve normal CFTR function[60]. - The median predicted survival age for individuals with cystic fibrosis born in the U.S. between 2020 and 2024 is just 65 years, highlighting the ongoing need for improved therapies[45]. Safety and Tolerability - SION-719 was generally well tolerated, with no serious adverse events reported, and 60% of participants experienced any treatment-emergent adverse events (TEAEs) across all doses[86]. - The most common TEAEs included headache (23%), diarrhea (10%), and nausea (8%), with no TEAEs leading to treatment discontinuation[87]. - SION-451 was also well tolerated, with 50% of participants experiencing any TEAEs, and no serious adverse events reported[98]. - The most frequent TEAEs for SION-451 included headache (18%) and influenza (5%), with no TEAEs leading to treatment discontinuation[99]. - SION-109 was generally well tolerated across all dose levels in the Phase 1 trial, with 38% of participants experiencing any treatment-emergent adverse events (TEAEs) and no serious adverse events reported[140][141]. - The most frequent TEAEs included headache (13%), abdominal pain (5%), and increased alanine aminotransferase (5%)[142]. - The majority of adverse events reported in clinical trials for SION-2222 were mild to moderate, indicating a favorable safety profile[129]. Mechanism of Action and Preclinical Findings - Preclinical studies indicated that SION-719 and SION-451 increased NBD1 thermal stability by approximately 16°C compared to ETI[106]. - Binding affinity for SION-719 to F508del-NBD1 was approximately 4.3 nM, while SION-451 had a binding affinity of approximately 2.4 nM[108]. - Both SION-719 and SION-451 showed potential to restore F508del-CFTR folding and maturation to levels similar to wild-type CFTR[109]. - SION-719 and SION-451 improved the half-life of F508del-CFTR to 12.6 hours and 14.2 hours respectively, compared to 1.7 hours for F508del-CFTR alone[116]. - Treatment with SION-719 as a single agent demonstrated a greater effect on F508del maturation than ETI, achieving wild-type levels of corrected F508del-CFTR protein[112]. - In the CFHBE model, SION-719 and SION-451 improved F508del-CFTR activity to levels near those observed with the triple combination ETI[120]. - SION-451 in combination with SION-2222 or SION-109 showed significant improvements in CFTR function, with half-lives reaching 16.4 hours[116]. Intellectual Property and Licensing - The company aims to expand and protect its intellectual property estate to maximize the value of its pipeline[48]. - The company co-owns a patent family with Sanofi covering SION-719 and SION-451, with a statutory expiration date of September 2043[159]. - The patent family covering SION-109 has a statutory expiration date of November 2040, indicating a strong intellectual property position[160]. - The company entered into a license agreement with Sanofi, paying an upfront fee of $1.5 million and a reimbursement of $0.3 million for R&D expenses, with potential milestone payments of up to $40.0 million[167]. - The company is required to pay royalties to Sanofi in the low single-digit percentage range based on net sales of licensed products, with the royalty term terminating upon the expiration of the last-to-expire patent claim or regulatory exclusivity[167]. - The company entered into a license agreement with AbbVie, paying an upfront fee of $5.0 million and issuing 1,414,445 shares of common stock, with potential milestone payments of up to $360.0 million[180]. - The company is required to pay royalties to AbbVie in the low to mid single-digit percentage range based on net sales of licensed products, with the royalty term terminating similarly to the Sanofi agreement[180]. - The AbbVie License Agreement includes a right of first negotiation for AbbVie regarding any commercial license transaction prior to Phase 3 clinical trials[181]. - The company has assumed all global development and commercialization responsibilities for three clinical-stage CFTR modulator therapies under the AbbVie License Agreement[178]. Regulatory Compliance and Market Considerations - Regulatory compliance is critical, with extensive requirements imposed by the FDA and other authorities, necessitating significant time and financial resources for drug development and approval[186]. - The company must submit an IND to the FDA before beginning the first clinical trial in the U.S., which includes preclinical test results and manufacturing information[190]. - Clinical trials are conducted in three phases: Phase 1 focuses on safety and dosage, Phase 2 evaluates efficacy and safety in a limited patient population, and Phase 3 generates data for FDA approval[199]. - The FDA has a goal of reviewing standard NDAs within ten months and priority NDAs within six months from the filing date[208]. - The FDA may require a Risk Evaluation and Mitigation Strategy (REMS) as a condition of approval to ensure the drug's benefits outweigh its risks[207]. - A Complete Response Letter from the FDA indicates that the application will not be approved in its current form and outlines deficiencies that must be addressed[211]. - The company must submit progress reports detailing clinical trial results at least annually to the FDA[200]. - The FDA conducts inspections of manufacturing facilities to ensure compliance with cGMP requirements before approving an NDA[205]. - The company must disclose results of clinical trials after completion, with penalties for failure to register or report results timely[197]. - Pediatric data requirements must be met for certain NDAs, and the FDA may grant deferrals or waivers under specific circumstances[209]. - The FDA may impose conditions on approved products that can significantly affect market potential and profitability, including post-approval studies and risk management mechanisms[212]. - Orphan Drug Designation allows for exclusivity for seven years if the product is the first FDA-approved treatment for a rare disease, with specific conditions for maintaining exclusivity[215]. - The FDA's Fast Track designation facilitates expedited review for drugs addressing serious conditions, allowing rolling submissions of NDA sections[218]. - Breakthrough Therapy designation provides intensive guidance from the FDA and similar benefits to Fast Track, aimed at drugs showing substantial improvement over existing therapies[220]. - Priority Review designation shortens the FDA's review timeline from ten months to six months for drugs that significantly improve safety and effectiveness[221]. - Accelerated Approval allows drugs to be approved based on surrogate endpoints, contingent on post-approval confirmatory studies to verify clinical benefits[222]. - The Hatch-Waxman Amendments establish a five-year non-patent exclusivity period for new chemical entities, delaying ANDA submissions until this period expires[226]. - Three years of market exclusivity is granted for non-NCE NDAs if new clinical investigations are essential for approval, protecting new indications or dosages[227]. Competitive Landscape - The company faces substantial competition from established players like Vertex, which has multiple approved CFTR modulators, including Trikafta[152]. - The CF patient populations are well-characterized, with treatment typically occurring at centralized CF care centers, suggesting a focused approach for commercialization[150].

Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated in mid-2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is on track with topline data anticipated in mid-2026 Maintained strong cash position with approximately $310.3 million in cash and cash equivalents, exp ...

Sionna Therapeutics On a Mission to Revolutionize the Cystic Fibrosis Treatment Paradigm March 2nd 2026 Disclaimers and forward-looking statements This presentation contains forward-looking statements of Sionna Therapeutics, Inc. ("Sionna", "the Company", "we", "us", or "our") that involve substantial risks and uncertainties. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding our goal of transforming the treatment paradi ...

Core Insights - Sionna Therapeutics is advancing its clinical pipeline for cystic fibrosis (CF) with ongoing trials for NBD1 stabilizers SION-719 and SION-451, with topline data expected in mid-2026 [1][2] Pipeline Updates - The PreciSION CF Phase 2a proof-of-concept trial for SION-719 is evaluating its safety and efficacy as an add-on to standard care in CF patients, with topline data anticipated in mid-2026 [1][4] - The Phase 1 trial for SION-451, in combination with SION-2222 and SION-109, is also on track, with topline data expected in mid-2026 [1][4] - Data presented at the 2025 North American Cystic Fibrosis Conference showed that both SION-719 and SION-451 were well tolerated and increased the half-life of F508del-CFTR protein to levels seen in wild-type [4] Financial Performance - Research and development expenses for Q4 2025 were $15.2 million, up from $14.3 million in Q4 2024, and for the full year, they totaled $60.3 million compared to $57.3 million in 2024 [3] - General and administrative expenses for Q4 2025 were $8.4 million, compared to $3.9 million in Q4 2024, and for the full year, they were $28.7 million versus $13.3 million in 2024 [4] - The net loss for Q4 2025 was $20.4 million, compared to a net loss of $15.8 million in Q4 2024, and for the full year, the net loss was $75.3 million compared to $61.7 million in 2024 [5] Cash Position - As of December 31, 2025, Sionna had approximately $310.3 million in cash and cash equivalents, which is expected to fund operations into 2028 [6][11]

Core Insights - Sionna Therapeutics is focused on developing innovative treatments for cystic fibrosis (CF) by normalizing the function of the CFTR protein [2] - The company is advancing a pipeline of small molecules aimed at correcting defects caused by the F508del genetic mutation, which is significant for improving clinical outcomes for CF patients [2] Company Overview - Sionna Therapeutics is a clinical-stage biopharmaceutical company dedicated to revolutionizing CF treatment through novel medicines [2] - The company's approach involves stabilizing the nucleotide binding domain 1 (NBD1) of the CFTR protein, which is believed to be crucial for enhancing patient quality of life [2] - Sionna is also developing complementary CFTR modulators to work synergistically with its NBD1 stabilizers [2] Investor Engagement - Sionna will participate in investor events, including the TD Cowen 46 Annual Health Care Conference on March 2, 2026, and the Leerink Partners Global Healthcare Conference on March 10, 2026 [4] - Live webcasts of these presentations will be available on Sionna's Investor Relations website, with replays accessible afterward [1]

Summary of Sionna Therapeutics Conference Call Company Overview - **Company**: Sionna Therapeutics (NasdaqGM:SION) - **Industry**: Biotechnology, specifically focused on Cystic Fibrosis (CF) treatment - **History**: Founded in late 2019, building on over 15 years of research from Genzyme and Sanofi [2][3] Core Points and Arguments - **Mission**: To revolutionize CF treatment using first-in-class NBD1 stabilizers, aiming to disrupt a market currently dominated by a single player [2] - **Upcoming Catalysts**: - **PreciSION CF Study**: A Phase 2a proof of concept study testing SION-719 in combination with TRIKAFTA, expected data readout in mid-2026 [3][4] - **SION-451 Study**: Testing in combination with other mechanisms, also expecting data in mid-2026 [4][5] - **NBD1 Biology**: - NBD1 is a critical part of the CFTR protein, with the F508del mutation affecting approximately 90% of CF patients [6][7] - Current treatments like TRIKAFTA do not directly stabilize NBD1, which is crucial for correcting CFTR function [8][9] - Previous attempts by companies like Pfizer and Vertex to target NBD1 were unsuccessful due to its challenging chemistry [9] Clinical Development - **PreciSION CF Study Design**: - A crossover study involving F508del homozygous patients already on TRIKAFTA, measuring sweat chloride levels as a biomarker for CFTR function [15][16] - Aiming for a clinically meaningful improvement of at least 10 millimoles per liter in sweat chloride [25][26] - **Patient Population**: Focused on a homogeneous group of F508del homozygous patients to minimize variability [20][22] - **Expected Outcomes**: - Improvement in sweat chloride levels, which is expected to correlate with FEV1 improvements [26][28] - The study is powered to detect a significant change in sweat chloride, which is a key indicator of treatment efficacy [18] Market Insights - **Market Size**: The CF market is currently valued at approximately $12 billion, projected to grow to $15-$17 billion in the next five years [45] - **Financial Position**: Sionna ended Q3 with $325 million in cash, providing a runway into 2028 [45] Additional Considerations - **Dual Combination Strategy**: The company is exploring combinations of NBD1 stabilizers with other correctors to achieve optimal CFTR function [12][14] - **Commercial Strategy**: Depending on the outcomes of the PreciSION study, Sionna may consider pursuing add-on therapies alongside dual combinations [36][38] - **Regulatory and Development Timeline**: Specific timelines for data announcements will be refined as patient enrollment progresses [32][33] This summary encapsulates the key points discussed during the conference call, highlighting Sionna Therapeutics' strategic focus, clinical development plans, and market potential in the CF treatment landscape.